HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, K. M. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Anderson, K. M. Articles by Topol, E. J.

CLINICAL STUDY: INTERVENTIONAL CARDIOLOGY

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

Keaven M. Anderson, PhD^*, Robert M. Califf, MD, FACC, Gregg W. Stone, MD, FACC^**, Franz-Josef Neumann, MD, FACC^||, Gilles Montalescot, MD^¶, Dave P. Miller, MS, James J. Ferguson, III, MD, FACC, James T. Willerson, MD, FACC, Harlan F. Weisman, MD, FACC^* and Eric J. Topol, MD, FACC

^* Centocor, Malvern, Pennsylvania, USA
Duke University, Durham, North Carolina, USA
Texas Heart Institute, Houston, Texas, USA
Lewin-TAG, Inc., San Francisco, California, USA
^|| Deutsches Herzzentrum, Munich, Germany
^¶ Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
^** Lenox Hill Hospital, New York, New York, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA

Manuscript received February 22, 2000; revised manuscript received February 13, 2001, accepted March 1, 2001.

Reprint requests and correspondence: Dr. Keaven Anderson, Centocor, Inc., 200 Great Valley Parkway, Malvern, Pennsylvania 19355-1307
andersonk{at}centocor.com

	Abstract

Top Abstract Methods Results Discussion References

 
OBJECTIVES

The goal of this study was to test: 1) if platelet glycoprotein IIb/IIIa (GP IIb/IIIa) blockade with abciximab bolus plus 12-h infusion reduces mortality after percutaneous coronary intervention (PCI); 2) if prevention of early myocardial infarction (MI) after PCI is a mechanism for reducing mortality; and 3) for risk factors for mortality after PCI.

BACKGROUND

Studies of PCI suggest that MI after intervention is predictive of mortality. Abciximab, a platelet GP IIb/IIIa receptor inhibitor, has consistently reduced the incidence of MI among PCI patients in several trials. The presumed mechanism is prevention of platelet thrombus associated with vessel wall injury and downstream embolization into the microcirculation.

METHODS

In eight trials, 5,154 patients were randomized to a regimen comprising conventional therapy plus a bolus of abciximab within 1 h before PCI followed by a 12-h infusion; 4,136 controls were randomized to conventional therapy alone. Patient follow-up from six months to three years was available. Survival differences are examined using proportional hazards regression and survival curves.

RESULTS

A hazard ratio of 0.71 (95% confidence interval 0.57 to 0.89; p = 0.003) suggests a mortality benefit with abciximab. The absolute reduction in mortality was estimated to be 0.5% through 30 days, 0.7% through six months, 0.9% through one year and 1.8% through three years. Early MI explained 18% of the observed mortality benefit at one year. Multivariate regression suggests that patients with advanced cardiovascular disease may derive the greatest mortality benefit from abciximab.

CONCLUSIONS

The evidence from 9,290 randomized PCI patients shows a mortality benefit provided by abciximab bolus plus 12-h infusion.

Abbreviations and Acronyms   ADMIRAL = Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up   CABG = coronary artery bypass grafting   CADILLAC = Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications   CAPTURE = C7E3 AntiPlatelet Therapy in Unstable REfractory angina trial   CHF = congestive heart failure   CI = confidence interval   EPIC = Evaluation of 7E3 in Preventing Ischemic Complications trial   EPILOG = Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIa/IIIb blockade trial   EPISTENT = Evaluation of Platelet Inhibition in STENTing trial   ERASER = Evaluation of ReoPro And Stenting to Eliminate Restenosis   GP IIb/IIIa = glycoprotein IIb/IIIa   HR = hazard ratio   ISAR-2 = Intracoronary Stenting and Antithrombotic Regimen-2 trial   MI = myocardial infarction   PCI = percutaneous coronary intervention   PTCA = percutaneous transluminal coronary angioplasty   PVD = peripheral vascular disease   RAPPORT = ReoPro and Primary PTCA Organization and Randomized Trial

Abciximab prevented acute coronary complications of PCI in randomized trials enrolling over 12,000 patients (2–11). In the Evaluation of 7E3 in Preventing Ischemic Complications (EPIC) trial (2), a bolus of abciximab within 1 h before PCI plus a 12-h abciximab infusion prevented thrombotic events in patients at high risk for ischemic complications. Subsequently, this regimen was studied in several thousand low- and high-risk patients in seven additional randomized trials (3–9). More than a million patients have been treated with this regimen worldwide since its approval in 1994. While MI and the need for urgent repeat revascularization were reduced in individual studies, early mortality rates were low, and differences were not statistically significant.

The objective of this study was to analyze mortality differences after PCI in the eight randomized trials including standard therapy with heparin and aspirin (placebo) and standard therapy plus an abciximab bolus within 60 min before PCI followed by a 12-h abciximab infusion. Follow-up of six months to three years from these trials is available. This analysis includes all follow-up from all trials.

	Methods

Top Abstract Methods Results Discussion References

 
Population and follow-up.   All follow-up data are included from all randomized, controlled studies of patients undergoing PCI where a 0.25 mg/kg bolus of abciximab within 60 min before PCI followed by a 12-h infusion of abciximab was studied. These data include the three-year follow-up from the EPIC trial (12), one-year follow-up from the Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIa/IIIb blockade (EPILOG) (13) Evaluation of Platelet Inhibition in STENTing (EPISTENT) (14) and Intracoronary Stenting and Antithrombotic Regimen-2 (ISAR-2) (7) trials and six month follow-up from the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) (5), Evaluation of ReoPro And Stenting to Eliminate Restenosis (ERASER) (6), Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up (ADMIRAL) (8) and Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) (9) trials. All trials were randomized and controlled. All were double-blind with a placebo except the ISAR-2 and CADILLAC trials, which were open-label after randomization. In the ERASER trial, one of three arms included an infusion of abciximab that continued for 24 h after PCI. In all other active arms considered above, the abciximab infusion was 12 h. In each case, patients randomized to a common intervention were compared. Regimens with abciximab given only as a bolus or discontinued early after percutaneous transluminal coronary angioplasty (PTCA) were excluded from the emphasized analyses because of the early partial return of platelet function (15) when acute ischemic event rates are still relatively high. No incremental benefit in the rate of death, MI or urgent intervention was observed more than six h after treatment discontinuation when treatment was given as a bolus or discontinued within one h after PCI, while incremental benefit was observed after treatment when the infusion was continued (2,3,11,14). However, a complementary analysis included patients with abciximab regimens not continuing for 12 h after PCI (EPIC bolus group, C7E3 AntiPlatelet Therapy in Unstable Refractory angina [CAPTURE] pilot trial [10], CAPTURE trial [11]). Patients in the EPISTENT trial in the balloon plus abciximab treatment group were also included in this analysis even though a balloon arm without abciximab was not studied. Trials testing other compounds that block the glycoprotein IIb/IIIa (GP IIb/IIIa) receptor in the setting of PCI (16–18) were not included. The first two of these PCI studies of small molecule GP IIb/IIIa inhibitors failed to show a significant reduction of the primary end point at 30 days, suggesting differences between molecules or their dosing. The head-to-head comparison of abciximab with tirofiban found abciximab to produce superior results for the composite end point of death, MI and urgent repeat revascularization (19). In addition, the pharmacology of abciximab is distinct: platelet function recovers only gradually with abciximab, and abciximab has a dual specificity for the _Vß₃ receptor on platelets, vascular smooth muscle cells and endothelial cells (20). Finally, an analysis combining all trials of GP IIb/IIIa inhibition showed no late mortality benefit with other GP IIb/IIIa inhibitors (21).

The types of patients studied were high-risk in the EPIC trial (acute MI, unstable angina, high-risk lesion characteristics), a broad population in the EPILOG trial (excluded only unstable angina meeting EPIC criteria and acute MI), acute MI in the RAPPORT, ISAR-2 and ADMIRAL trials, patients amenable to intracoronary stent placement in the ERASER trial, patients amenable to stent placement or angioplasty in the EPISTENT trial, acute MI patients amenable to stent in the CADILLAC study and unstable angina patients in the CAPTURE trial and its pilot.

Final follow-up was performed at a fixed, prespecified interval after randomization for all patients in each study with the exception of the EPIC trial. The EPIC follow-up was conducted primarily in 1995, while randomization was done primarily in 1992. Mortality follow-up in EPIC was complete through 2.5 to 3.5 years for 97% of patients. Three-years of follow-up is presented here to be consistent with previous presentation (12).

At least one year of follow-up and other patient data were available from the EPIC, EPILOG and EPISTENT trials. Multivariate proportional hazards regression modeling was performed for these studies. The association of early events (MI, urgent PCI, urgent coronary artery bypass graft surgery [CABG]) within 48 h of randomization with one-year mortality was also examined in these trials.

Statistical methods.   Analyses of all randomized patients (intention-to-treat) are presented. Patient survival and duration of follow-up were available on an individual patient basis. Survival of abciximab and control patients was compared using a proportional hazards regression model as implemented in the PHREG procedure (SAS Institute, Inc., Cary, North Carolina). Analyses were stratified by study and type of device (stent or balloon) to which a patient was assigned with a common hazard ratio (HR) assumed across strata. A 95% confidence interval (CI) for the HR for mortality for abciximab compared with control was computed by exponentiating the ends of the 95% CI for the regression coefficient. Corresponding p values using the Wald method are presented. For cases where no deaths occurred in the abciximab group, the partial likelihood was used to compute an exact upper 95% confidence bound for the HR. A likelihood ratio was used to test for an interaction of the treatment effect with device strategy planned at the time of randomization (stent or not); patients were stratified by device strategy in this model. A likelihood ratio test was also used to test for study-treatment interaction and to test for differential treatment effect in acute MI and other patients.

The Kaplan-Meier method was used for estimation of the probability of death in each treatment group of each study through the entire duration of follow-up. In addition, combined estimates of mortality with and without abciximab at 48 h, 7 days, 14 days, 30 days, 6 months and 1 year are presented by combining the individual Kaplan-Meier survival probability estimates. Each study was weighted by the total number of patients included (abciximab and control) in the analysis. This is analogous to the "age-adjustment" method (22) and corrects for imbalances in the proportion of patients randomized to placebo and abciximab in different studies; such imbalances could lead to a bias in estimates of treatment group differences.

Multivariate regression modeling with data from the EPIC, EPILOG and EPISTENT trials included baseline characteristics (age, gender, weight, cigarette smoking), intervention characteristics (intervention attempted, multiple segments attempted, multiple vessels attempted), history (unstable angina within 48 h, MI within seven days, PCI, CABG, peripheral vascular disease [PVD], stroke, hypertension, diabetes, congestive heart failure [CHF]) and treatment with abciximab. Models were stratified by study. As in other comparisons, bolus plus infusion abcixmab was compared with placebo for patients with a common intervention; thus, the bolus group from EPIC (no 12-h abciximab infusion after PCI) and the EPISTENT balloon arm (no control balloon arm) were excluded. Because of the large number of associations tested and the relatively small number of deaths available, interactions with treatment were not tested.

The one-year EPIC, EPILOG and EPISTENT data were also used to estimate the portion of mortality benefit explained by the early reduction in MI that abciximab provided. The proportion of patients who had both an early event (death, MI or urgent repeat revascularization) and died within one year was estimated for each treatment group using the Kaplan-Meier method; all patients were censored except those that had an event within 48 h of randomization and later died. The difference between treatment groups was divided by the overall difference in mortality between treatment groups at one year to estimate the portion of mortality reduction explained by the treatment reduction of early events.

	Results

Top Abstract Methods Results Discussion References

 
Table 1 compares mortality among PCI patients randomized to standard therapy (placebo) or to an abciximab bolus immediately before PCI followed by a 12-h infusion using a proportional hazards regression model. Lower mortality with abciximab was observed in each study, with a significant reduction at one year in the EPISTENT trial when abciximab was combined with stenting (p = 0.043). Combining studies increased the strength of evidence for a reduction in mortality with the abciximab bolus plus 12-h infusion compared with standard therapy as indicated by an HR of 0.71 (95% CI: 0.57, 0.89; p = 0.003). When the analysis in the bottom line of Table 1 was repeated, eliminating follow-up after one year, the association remained (HR 0.74; 95% CI: 0.58, 0.94; p = 0.012). The association remained significant after including all follow-up of all randomized patients according to randomized treatment assignment including all abciximab regimens (HR 0.79; mortality in 193/4,801 placebo patients, 234/7,305 abciximab patients; 95% CI: 0.65, 0.96; p = 0.017). This included the EPIC bolus group (54 deaths/695 randomized), the CAPTURE pilot (10) with 12 weeks of follow-up (0/30 deaths abciximab; 1/30 deaths placebo), CAPTURE (11) with six months of follow-up (17/630 deaths abciximab; 14/635 deaths placebo) and the EPISTENT balloon plus abciximab group (17/796 deaths). Excluding any single trial from the final analysis in Table 1 results in a p value of no higher than 0.013. No treatment-study interaction was found (the four smaller studies were combined for this analysis; p = 0.64).

Figure 1 shows a relatively high mortality rate in each treatment group in the first two weeks after randomization with a somewhat lower mortality rate thereafter through six months. The relative mortality reduction with abciximab compared with placebo was not statistically different (p = 0.80) in the first two weeks (HR: 0.68; 95% CI: 0.46, 1.01) than it was after two weeks (HR: 0.73; 95% CI: 0.56, 0.96). Table 2 displays mortality rates for different time periods. Analyses for fixed durations of six months (p = 0.040) and one year (p = 0.031) reached nominal significance. The EPIC trial is the only trial with follow-up after one year. Between one and three years, the absolute mortality reduction with abciximab grew from 0.21% (4.45% placebo, 4.24% abcixmab) to 1.81% (8.58% placebo, 6.77% abciximab [12]).

View larger version (20K): [in this window] [in a new window]   Figure 1 Mortality over six months for all studies combined by patient randomization to standard therapy (placebo) versus standard therapy plus abciximab bolus within 1 h before percutaneous coronary intervention followed by a 12-h infusion.

The rate of early end point events (death, MI, urgent PCI, urgent CABG within 48 h of randomization) was reduced from 9.5% in the placebo group to 4.9% in the abciximab group in the combined EPIC, EPILOG and EPISTENT analysis. The risk of dying between 48 h and one year was higher (HR 3.18; 95% CI: 2.18, 4.63) among the patients alive at 48 h who already had experienced an early MI or urgent intervention compared with those who did not. This increased risk associated with early end point events is similar to the results reported in previous studies (1). Nevertheless, most of the observed mortality from randomization to one year was among patients who did not have early end point events. In the placebo group, 73% of deaths within one year were among patients without early events (2.17% of patients had no early event and died within one year of a total of 2.97% of placebo patients who died); this figure was 70% in the abciximab group (1.5% of 2.14%) (Fig. 2). Furthermore, most mortality benefit with abciximab was observed among the patients who did not have early events: 0.83% absolute mortality benefit was observed in the abciximab group overall (2.97% – 2.14%), with 0.67% (2.17% – 1.5%) or 82% of the total mortality difference observed among the patients without death, MI or urgent PCI or CABG within 48 h of randomization. In order to test the association of mortality with treatment among patients without early events, patients were censored at the time of an event (death, MI or urgent PCI or CABG within 48 h of randomization): one year of follow-up was used for EPISTENT and EPILOG and three years for EPIC. Among patients without early events, the HR for mortality with abciximab compared with placebo patients was 0.60 (p = 0.002).

View larger version (30K): [in this window] [in a new window]   Figure 2 Difference in one-year mortality in the EPIC, EPILOG and EPISTENT trials by randomized treatment assignment partitioned among patients with and without an early end point event (death, myocardial infarction or urgent percutaneous coronary intervention or coronary artery bypass grafting within 48 h of of randomization). Solid box = with event < 48 h; open box = without event < 48 h. For acronym definitions, see Abbreviations and Acronyms box.

	Discussion

Top Abstract Methods Results Discussion References

Multivariate regression suggested that patients with more advanced cardiovascular disease (older age, with CHF, hypertension, and/or multivessel disease) were at higher risk of mortality. Treatment interactions with risk factors for mortality were not tested because of the relatively large number of factors and the relatively small number of deaths in the combined studies. The model suggests that patients without any of these risk factors would have a low risk of mortality regardless of treatment: that the mortality benefit is greatest among patients with advanced cardiovascular disease. An analysis specifically examining diabetics in the combined EPIC, EPILOG and EPISTENT trials suggests that diabetics might receive a particular mortality benefit from abciximab (23). The three-year EPIC follow-up suggested that those with severe unstable angina might have a greatly reduced mortality after abciximab treatment (24). Since patients with angina this severe were excluded from EPILOG and may have been preferentially eliminated from EPISTENT, the results presented here do not clarify the relative mortality benefit among patients with acute coronary syndromes at the time of PCI.

Selection of analysis presented.   Although a meta-analysis of all GP IIb/IIIa inhibition studies using many agents in both PCI and medical therapy for unstable angina/non-Q-wave MI showed no mortality benefit at six months (21), differences in mortality rates among the agents included in the meta-analysis were not presented. In this study, the HR estimation assumed both early and late mortality were equally reduced by abciximab. We emphasized the abciximab regimen that has been most widely studied, has demonstrated the greatest acute benefit (19,20) and is in use worldwide. Abciximab regimens with concurrent placebo controls using the same interventional strategy were emphasized, excluding the EPISTENT PTCA/abciximab group. However, an intention-to-treat analysis of PCI studies comparing all abciximab regimens to placebo using all available mortality follow-up confirmed the results presented.

Possible mechanisms of benefit.   It is likely that the most frequent triggering for periprocedural MI is atherosclerotic particulate material that is microembolized in the coronary vasculature coupled with local vasoconstriction associated with a platelet aggregation response (25). Abciximab blocks platelet aggregation both at the site of plaque injury and downstream at the site of vascular embolism. Thus, marked lessening of necrosis is likely and the chance for developing arrhythmic foci is reduced, which are a likely cause of the excess late sudden death events reported in multiple series (1). However, only 18% of the mortality benefit was estimated to be attributable to early events, and abciximab significantly reduced mortality (p = 0.002) compared with placebo among patients without early events. Thus, although patients with events within 48 h after PCI are more likely to die during follow-up, most late deaths occur among patients without these early events. Therefore, the survival benefit of abciximab benefit is twofold. First, early events associated with increased mortality are prevented. Second, survival is improved among the majority of patients undergoing PCI who do not experience early events.

The measurement of early MI using routine enzyme measurement may not detect all early benefit provided by abciximab. There is a possibility that some platelet emboli not causing an infarction as defined in the trials are eventually clinically significant and are prevented by abciximab. However, other possible factors explaining the abciximab mortality benefit among patients without early MI may be related to pharmacologic characteristics of abciximab other than the immediate prevention of platelet aggregation in the periprocedural period. These include prolonged, gradually tapering platelet inhibition during the first two to three weeks after PCI (20). This enhances microcirculatory blood flow and improves ventricular function in patients with ongoing plaque instability after PCI, as has been reported in patients with acute MI undergoing intracoronary stenting with abciximab (7). Other possibilities contributing to improved survival include beneficial effects on longer-term arterial passivation. Abciximab blocks not only GP IIb/IIIa on platelets but also has equivalent blocking affinity for the _Vß₃ receptor (20,26) on platelets, vascular smooth muscle cells and endothelial cells and, in addition, has demonstrable inhibition of the Mac-1 receptor on activated monocytes and macrophages (27). These integrin receptors and cells have been implicated in both the acute and chronic response to arterial plaque injury and atherothrombosis (28–31). By blocking these receptors with tapered recovery after PCI, abciximab may affect long-term vessel healing and stability.

Study limitations.   Analysis of mortality across studies was not prespecified. Only the EPIC trial had follow-up of more than one year. The patient populations in these studies varied in their enrollment characteristics. The nature of PCI changed over the span of several years when these studies were conducted, with stenting rarely being used at the time of EPIC to its becoming a standard of care at the time of EPISTENT. Although there have been over 20,000 patients in studies of GP IIb/IIIa inhibitors cited here, there are still too few deaths in these studies to adequately assess whether there is a differential mortality benefit between agents, regimens and patient populations. Analyses where early follow-up is excluded should be considered descriptive. Despite these limitations, a mortality reduction was observed consistently across time periods, devices and trials, suggesting that the results can be generalized to a broad patient population undergoing PCI with the abciximab bolus plus 12-h infusion regimen.

Conclusions.   The accumulated data from randomized clinical trials provides robust evidence of a mortality benefit provided by a bolus of abciximab within 1 h before PCI followed by a 12-h infusion. Further follow-up to extend the long-term observational window would be worthwhile.

	Acknowledgments

 
The authors acknowledge the following individuals who have contributed data or provided review of the manuscript. Rotterdam: Maarten Simoons; Eli Lilly, France: Philippe Pinton; Centocor: Elliot Barnathan, Richard Melsheimer.

	Footnotes

 
Supported by Centocor, Malvern, Pennsylvania.

	References

Top Abstract Methods Results Discussion References

 

1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251[Abstract/Free Full Text]
2. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
3. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
4. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87–92[Medline]
5. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734–741[Abstract/Free Full Text]
6. ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100:799–806[Abstract/Free Full Text]
7. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;34:915–921
8. Montalescot G, Barragan P, Wittenberg O, et al. Clinical benefits of platelet glycoprotein IIb/IIIa blockade with coronary stenting in acute myocardial infarction. N Engl J Med 2001. In Press.
9. Stone GW, Grines CL, Cox DA, et al. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction—primary end point analysis from the CADILLAC trial. (abstr)Circulation. 2000;102:II664
10. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative study group. Circulation. 1994;89:596–603[Abstract/Free Full Text]
11. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. (Published erratum appears in Lancet 1997;350:744)Lancet. 1997;349:1429–1435[CrossRef][Medline]
12. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin ß₃ blockade with percutaneous coronary intervention. EPIC investigator group: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997;278:479–484[Abstract]
13. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 1999;99:1951–1958[Abstract/Free Full Text]
14. EPISTENT InvestigatorsTopol EJ, Mark DB, Lincoff AM, et al. Outcomes at one year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet. 1999;354:2019–2024[CrossRef][Medline]
15. Tcheng JE, Ellis SG, George BS, et al. Phamacodynamics of chimeric glycoproteinc IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757–1764[Abstract/Free Full Text]
16. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422–1428[CrossRef][Medline]
17. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
18. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037–2044[CrossRef][Medline]
19. Topol EJ, Moliterno DJ, Herrmann HC, et al., for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary intervention. N Engl J Med 2001. In Press.
20. Kereiakes D, Runyon JP, Broderick TM, Shimshak TM. IIb’s are not IIb’s. Am J Cardiol. 2000;85:23C–31C[Medline]
21. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835[Abstract/Free Full Text]
22. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley; 1981. 2nd ed.
23. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–928[Abstract/Free Full Text]
24. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC investigators: Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol. 1997;30:149–156[Abstract]
25. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation. 1989;80:198–205[Abstract/Free Full Text]
26. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 1998;98:1085–1091[Abstract/Free Full Text]
27. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed agains the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528–535[Abstract/Free Full Text]
28. Byzova TV, Rabbani R, D’Souza SE, Plow EF. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost. 1998;80:726–734[Medline]
29. Meisel SR, Shapiro H, Radnay J, et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol. 1998;31:120–125[Abstract/Free Full Text]
30. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95:10134–10139[Abstract/Free Full Text]
31. Srivatsa SS, Fitzpatrick LA, Tsao PW, et al. Selective _vß₃ integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin _vß₃ and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36:408–428[Abstract/Free Full Text]

This article has been cited by other articles:

				C. Bode and K. Huber Antiplatelet therapy in percutaneous coronary intervention Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A13 - A20. [Abstract] [Full Text] [PDF]

				P. B. Berger and S. V. Manoukian Bleeding Is Bad.... Isn't It? Circulation, December 11, 2007; 116(24): 2776 - 2778. [Full Text] [PDF]

				K. Thygesen, J. S. Alpert, H. D. White, and on behalf of the Joint ESC/ACCF/AHA/WHF Task Force Universal Definition of Myocardial Infarction J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2173 - 2195. [Full Text] [PDF]

				K. Thygesen, J. S. Alpert, H. D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force, TASK FORCE MEMBERS: Chairpersons: Kristian Thygese, Biomarker Group: Allan S. Jaffe, Coordinator (USA), ECG Group: Bernard Chaitman, Co-ordinator (USA), P, Imaging Group: Richard Underwood, Coordinator (UK), Intervention Group: Jean-Pierre Bassand, Co-ordina, Clinical Investigation Group: Paul W. Armstrong, C, et al. Universal Definition of Myocardial Infarction Circulation, November 27, 2007; 116(22): 2634 - 2653. [Full Text] [PDF]

				Task Force Members, K. Thygesen, J. S. Alpert, H. D. White, Biomarker Group, A. S. Jaffe, F. S. Apple, M. Galvani, H. A. Katus, L. K. Newby, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Eur. Heart J., October 2, 2007; 28(20): 2525 - 2538. [Full Text] [PDF]

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				P. Schiano and P. Gabriel Steg Measurement and prevention of myocardial injury during percutaneous coronary intervention Heart, June 1, 2007; 93(6): 656 - 657. [Abstract] [Full Text] [PDF]

				G. Montalescot, D. Antoniucci, A. Kastrati, F. J. Neumann, M. Borentain, A. Migliorini, C. Boutron, J.-P. Collet, and E. Vicaut Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up Eur. Heart J., February 2, 2007; 28(4): 443 - 449. [Abstract] [Full Text] [PDF]

				D. Antoniucci Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A32 - A36. [Abstract] [Full Text] [PDF]

				T Heer, U Zeymer, C Juenger, A K Gitt, H Wienbergen, R Zahn, M Gottwik, J Senges, and for the Acute Coronary Syndromes (ACOS) Registry I Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice Heart, October 1, 2006; 92(10): 1484 - 1489. [Abstract] [Full Text] [PDF]

				D. Cai, J. M. Holm, I. J. Duignan, J. Zheng, M. Xaymardan, A. Chin, V. L. T. Ballard, J. N. Bella, and J. M. Edelberg BDNF-mediated enhancement of inflammation and injury in the aging heart Physiol Genomics, February 23, 2006; 24(3): 191 - 197. [Abstract] [Full Text] [PDF]

				D. Mukherjee, E. J. Topol, M. E. Bertrand, S. D. Kristensen, H. C. Herrmann, F.-J. Neumann, S. J. Yakubov, J.-P. Bassand, R. R. McClure, G. W. Stone, et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up Eur. Heart J., December 1, 2005; 26(23): 2524 - 2528. [Abstract] [Full Text] [PDF]

				The ADMIRAL Investigators Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study Eur. Heart J., December 1, 2005; 26(23): 2520 - 2523. [Abstract] [Full Text] [PDF]

				J. W. Ryan, E. D. Peterson, A. Y. Chen, M. T. Roe, E. M. Ohman, C. P. Cannon, P. B. Berger, J. F. Saucedo, E. R. DeLong, S.-L. Normand, et al. Optimal Timing of Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry Circulation, November 15, 2005; 112(20): 3049 - 3057. [Abstract] [Full Text] [PDF]

				J. Kaehler, R. Koester, W. Billmann, C. Schroeder, H.-J. Rupprecht, T. Ischinger, R. Jahns, A. Vogt, M. Lampen, R. Hoffmann, et al. 13-year follow-up of the German angioplasty bypass surgery investigation Eur. Heart J., October 2, 2005; 26(20): 2148 - 2153. [Abstract] [Full Text] [PDF]

				D. E. Cutlip and R. E. Kuntz Cardiac Enzyme Elevation After Successful Percutaneous Coronary Intervention Is Not an Independent Predictor of Adverse Outcomes Circulation, August 9, 2005; 112(6): 916 - 923. [Full Text] [PDF]

				A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel Eur. Heart J., July 2, 2005; 26(14): 1379 - 1384. [Abstract] [Full Text] [PDF]

				W.H. W. Tang and A. M. Lincoff Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade: The Triad Revisited Circulation, December 14, 2004; 110(24): 3618 - 3620. [Full Text] [PDF]

				D. J. Cohen, A. M. Lincoff, T. A. Lavelle, H.-L. Chen, A. Bakhai, R. H. Berezin, D. Jackman, I. J. Sarembock, and E. J. Topol Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1792 - 1800. [Abstract] [Full Text] [PDF]

				G. Montalescot Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? Eur. Heart J., September 2, 2004; 25(18): 1562 - 1564. [Full Text] [PDF]

				G. Ndrepepa, A. Kastrati, F.-J. Neumann, C. Schmitt, J. Mehilli, and A. Schomig Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting Eur. Heart J., September 2, 2004; 25(18): 1635 - 1640. [Abstract] [Full Text] [PDF]

				A. M. Lincoff, N. S. Kleiman, D. J. Kereiakes, F. Feit, J. A. Bittl, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial JAMA, August 11, 2004; 292(6): 696 - 703. [Abstract] [Full Text] [PDF]

				G. Montalescot, M. Borentain, L. Payot, J. P. Collet, and D. Thomas Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis JAMA, July 21, 2004; 292(3): 362 - 366. [Abstract] [Full Text] [PDF]

				G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]

D. Antoniucci, A. Migliorini, G. Parodi, R. Valenti, A. Rodriguez, A. Hempel, G. Memisha, and G. M. Santoro Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival: A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab With Stenting Alone Circulation, April 13, 2004; 109(14): 1704 - 1706. [Abstract]